Doctor profile · Federal record
Dr. THOMAS BARTZOKIS, M.D.
Cardiovascular Disease Physician (CMS: CARDIOVASCULAR DISEASE (CARDIOLOGY)) · Interventional Cardiology Physician · BOCA RATON, FL
- NPI 1053355560
- Accepts Medicare
- MIPS 89.5 / 100 · 2023
- 43 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
1000 NW 9TH CT, SUITE 101
BOCA RATON, FL 334862268
(561) 368-4444
fax (561) 750-8368
Credentials & registration
- NPI registered
- June 2006 — 20 yrs on file
- Profile last updated
- February 19, 2021
- Year of graduation
- 1983 — 43 yrs since
- Specialty taxonomy
- 207RC0000X — NUCC code
- State licenses (2)
- Florida #ME 57525 · Florida #ME57525
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1053355560. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
8,613
Distinct HCPCS
10
Medicare allowed
$746,246
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 2,297 | 1,541 | $130 | |
93000 |
Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,430 | 1,309 | $15 | |
G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 520 | 69 | $37 | |
A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose | 465 | 234 | $111 | |
J2785 |
Injection, regadenoson, 0.1 mg | 462 | 116 | $54 | |
93298 |
Evaluation of cardiac rhythm monitor system, remote up to 30 days | 449 | 58 | $27 | |
93306 |
Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 419 | 416 | $198 | |
93296 |
Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 399 | 123 | $22 | |
93294 |
Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 392 | 120 | $30 | |
99232 |
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 319 | 153 | $82 |
In context: peer comparison
Among 15 peers in this city , average services per provider: 279. This provider delivers 31× the peer median.Open Payments
Industry payments received
All-time total
$1,631
Transactions
99
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 47 | $304.69 | |
| Abbott Laboratories | 5 | $290.72 | |
| PFIZER INC. | 12 | $225.55 | |
| E.R. Squibb & Sons, L.L.C. | 10 | $148.17 | |
| Merck Sharp & Dohme LLC | 6 | $135.72 | |
| Regeneron Healthcare Solutions, Inc. | 2 | $76.93 | |
| Kestra Medical Technology Services, Inc. | 2 | $59.06 | |
| Amgen Inc. | 3 | $55.31 | |
| Kiniksa Pharmaceuticals International, plc | 3 | $54.37 | |
| SANOFI-AVENTIS U.S. LLC | 2 | $50.11 | |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $45.88 | |
| Boston Scientific Corporation | 2 | $31.70 | |
| Philips North America LLC | 1 | $31.69 | |
| CVRx, Inc. | 1 | $25.99 | |
| AGEPHA Pharma FZ LLC | 1 | $23.35 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
4,488
Patients
1,392
Total drug cost
$1,228,027
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Eliquis (Apixaban) | Brand | 494 | 133 | $628,239 |
| Metoprolol Succinate | Generic | 482 | 161 | $9,030 |
| Rosuvastatin Calcium | Generic | 480 | 152 | $9,940 |
| Amlodipine Besylate | Generic | 462 | 159 | $4,037 |
| Atorvastatin Calcium | Generic | 403 | 127 | $4,390 |
| Losartan Potassium | Generic | 393 | 125 | $5,077 |
| Furosemide | Generic | 286 | 108 | $2,007 |
| Repatha Sureclick (Evolocumab) | Brand | 278 | 45 | $250,090 |
| Xarelto (Rivaroxaban) | Brand | 221 | 66 | $293,960 |
| Ezetimibe | Generic | 183 | 58 | $8,390 |